Brodalumab Approved for Plaque Psoriasis
The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other systemic therapies. The treatment, which is administered as a subcutaneous injection, binds to the IL-17 receptor and inhibits inflammatory signaling by preventing the binding of several IL-17 types to the receptor.
You Might Also Like
Explore This IssueApril 2017
Also By This Author
Brodalumab has a Boxed Warning for risks in patients with a history of suicidal thoughts or behavior. Therefore, the treatment was approved with a Risk Evaluation and Mitigation Strategy (REMS). The REMS involves a one-time enrollment for physicians and a one-time informed consent for patients. Suicidal ideation and suicidal behavior have been reported with this agent.
In three randomized, placebo-controlled clinical trials, the safety and efficacy of brodalumab was established in 4,373 adults with moderate to severe plaque psoriasis who were candidates for systemic therapy or phototherapy. More brodalumab-treated patients compared with placebo-treated patients achieved 100% improvement in the psoriasis area and severity index (PASI100). This primary endpoint meant that patients had skin that was clear, or almost clear, at the end of the study.
The most common adverse reactions in clinical trials were arthralgia, diarrhea, fatigue, headache and oropharyngeal pain. Brodalumab is contraindicated in patients with Crohn’s disease. Serious infections have occurred in patients treated with the agent. Therefore, physicians should exercise caution when considering brodalumab use in patients with a chronic infection or a history of recurrent infection. Patients should be evaluated for tuberculosis infection prior to starting therapy.
Brodalumab will be marketed beginning in the second half of this year.
Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
Baricitinib, an investigational, oral, reversible inhibitor of Janus kinases JAK1 and JAK2, has completed the RA-BEAM, Phase 3 clinical trial.3 This study was a 52-week, randomized, double-blind, placebo- and active-controlled, parallel-group trial conducted in 26 countries.
Participants (n=1,307) were randomized into groups (3:3:2) to receive placebo, 4 mg baricitinib once daily or 40 mg of subcutaneous adalimumab every other week. Patients also continued background therapy with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), analgesics or glucocorticoids (≤10 mg prednisone or the equivalent per day). Placebo patients were switched to baricitinib at Week 24, maintaining study blinding. Most patients received background methotrexate (>99%) and the majority of patients had previously received at least two conventional synthetic DMARDs. The ACR20 response at Week 12 was the primary endpoint. Secondary endpoints included measurement of the DAS28, the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the Simplified Disease Activity Index (SDAI). The modified total Sharp score (mTSS) at Week 24 was also a secondary endpoint.